"Association of Proteinuria and Progression of Kidney Dysfunction in Sickle Cell Disease"Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

355 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-01

Study Completion Date

2021-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To describe change in ACR and eGFR during study follow-up, and assesss the association of baseline and change in ACR and eGFR, with progression of kidney failure and/or all-cause mortality.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Screening Patients With Sickle Cell Disease for Kidney Damage

NCT02239016

Sickle Cell Disease

COMPLETED

Kidney Function in Sickle Cell Anemia

NCT03277547

Sickle Cell Disease Kidney Failure, Chronic

ACTIVE_NOT_RECRUITING

Acute Kidney Injury in Patients With Sickle Cell Disease

NCT03105271

Sickle Cell Disease Kidney Injury Kidney Diseases +1 more

COMPLETED

Biological, Genetic and Environmental Involved in the Complications of Sickle Cell Disease

NCT04205123

Sickle Cell Disease

UNKNOWN

SCRIPT: Sickle Cell Risk in Pregnancy Tool

NCT06529042

Sickle Cell Disease Pregnancy, High Risk Pregnancy Complications

ENROLLING_BY_INVITATION

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a retrospective, non-interventional, secondary use of the data coming from the single-center secondary GEN-MOD study cohort at the Henri Mondor Hospital (Creteil, France). The GEN-MOD cohort includes 355 SCD patients.

The GEN-MOD data are accessible through the center's clinical and laboratory database and will be extracted and analyzed for the purpose of this study.

The enrolment in the GEN-MOD cohort lasted from 01 December 2002 until 01 March 2014. Follow-up occurred every six months and ranged from five to seventeen years and ended on 31 December 2019. The index date (baseline) for this study is the time of inclusion of patients in GEN-MOD cohort study

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Change in Albumin to Creatinine Ratio and Glomerular Filtration Rate Progression of Kidney Failure and or All-cause Mortality

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

no intervention study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults aged ≥ 18 years old.
* Confirmed diagnosis of SCD by Hb electrophoresis or high performance liquid chromatography. SCD genotypes HbSS, HbSβ0-thal.
* Availability of ACR and eGFR baseline records.